Epigallocatechin-3-gallate combined with alpha lipoic acid attenuates high glucose-induced receptor for advanced glycation end products (RAGE) expression in human embryonic kidney cells

Anais da Academia Brasileira de Ciencias

Volumn 85, Issue 2, 2013, Pages 745-752

  Leu, Jyh Gang ^a,b   Lin, Chin Yao ^b   Jian, Jhin Hao ^c   Shih, Chin Yu ^d   Liang, Yao Jen ^c  

^a FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^b SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

^c FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^d DEVELOPMENT CENTER FOR BIOTECHNOLOGY   (Taiwan)

Author keywords

Alpha lipoic acid; Anti oxidant; Diabetic nephropathy; Epigallocatechin gallate; Receptor of advanced glycation end products

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CATECHIN; DRUG DERIVATIVE; EPIGALLOCATECHIN GALLATE; GLUCOSE; INTERLEUKIN 6; THIOCTIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BIOSYNTHESIS; CELL STRAIN HEK293; HUMAN;

ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; CATECHIN; GLUCOSE; GLYCOSYLATION END PRODUCTS, ADVANCED; HEK293 CELLS; HUMANS; INTERLEUKIN-6; THIOCTIC ACID; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84879579521     PISSN: 00013765     EISSN: 16782690     Source Type: Journal    
DOI: 10.1590/S0001-37652013005000023     Document Type: Article

References (40)

1. ANSARI A, THOMAS S and GOLDSMITH D 2003 Assessing glycemic control in patients with diabetes and end-stage renal failure. Am J Kidney Dis 41: 523-531.
2. BOHLENDER JM, FRANKE S, STEIN G and WOLF G 2005 Advanced glycation end products and the kidney. Am J Physiol Renal Physiol 289: F645-659.
3. CHEN D, WAN SB, YANG H, YUAN J, CHAN TH and DOU QP 2011 EGCG, green tea polyphenols and their synthetic analogs and prodrugs for human cancer prevention and treatment. Adv Clin Chem 53: 155-177.
4. DE BOER IH, SUN W, CLEARY PA, LACHIN JM, MOLITCH ME, STEFFES MW and ZINMAN B 2011 Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med 365: 2366-2376.
5. DERUBERTIS FR, CRAVEN PA, MELHEM MF and SALAH EM 2004 Attenuation of renal injury in db/db mice over-expressing superoxide dismutase: evidence for reduced superoxide-nitric oxide interaction. Diabetes 53: 762-768.
6. EL Mowafy, Am Al-Gayyar MM, SALEM HA, El-Mesery ME and DARWEISH MM 2010 Novel chemotherapeutic and renal protective effects for the green tea (EGCG): role of oxidative stress and inflammatory-cytokine signaling. Phytomedicine 17: 1067-1075.
7. FUJITA H, FUJISHIMA H, CHIDA S, TAKAHASHI K, QI Z, KANETSUNA Y, BREYER MD, HARRIS RC, YAMADA Y and TAKAHASHI T 2009 Reduction of renal superoxide dismutase in progressive diabetic nephropathy. J Am Soc Nephrol 20: 1303-1313.
8. GIUGLIANO D, CERIELLO A and PAOLISSO G 1996 Oxidative stress and diabetic vascular complications. Diabetes Care 19: 257-267.
9. GOLBIDI S BADRAN and LAHER I 2011 Diabetes and alpha lipoic Acid. Front Pharmacol 2: 69.
10. GOYAL BR, PARMAR K, GOYAL RK and MEHTA AA 2011 Beneficial role of telmisartan on cardiovascular complications associated with STZ-induced type 2 diabetes in rats. Pharmacol Rep 63: 956-966.
11. HOLMAN RR, PAUL SK, BETHEL MA, MATTHEWS DR and NEIL HA 2008 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359: 1577-1589.
12. JATOI A, ELLISON N, BURCH PA, SLOAN JA, DAKHIL SR, NOVOYNY P, TAN W, FITCH TR ROWLAND KM, YOUNG CY and FLYNN PJ 2003 A phase II trial of green tea in the treatment of patients with and rogen independent metastatic prostate carcinoma. Cancer 97: 1442-1446.
13. JIAO B, WANG YS, CHENG YN, GAO JJ and ZHANG QZ 2011 Valsartan attenuated oxidative stress, decreased MCP-1 and TGF-beta1 expression in glomerular mesangial and epithelial cells induced by high-glucose levels. Biosci Trends 5: 173-181.
14. KATAOKA H 1998 Chromatographic analysis of lipoic acid and related compounds. J Chromatogr B Biomed Sci Appl 717: 247-262.
15. Kedziora-Kornatowska KZ, LUCIAK M, BLASZCZYK J and PAWLAK W 1998 Lipid peroxidation and activities of antioxidant enzymes in erythrocytes of patients with non-insulin dependent diabetes with or without diabetic nephropathy. Nephrol Dial Transplant 13: 2829-2832.
16. KHAN N, AFAQ F, SALEEM M, AHMAD N and MUKHTAR H 2006 Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate. Cancer Res 66: 2500-2505.
17. KOZLOV AV, GILLE L, STANIEK K and NOHL H 1999 ihydrolipoic acid maintains ubiquinone in the antioxidant active form by two-electron reduction of ubiquinone and one-electron reduction of ubisemiquinone. Arch Biochem Biophys 363:148-154.
18. LEE SJ and LEE KW 2007 Protective effect of (-)-epigallocatechin gallate against advanced glycation endproducts-induced injury in neuronal cells. Biol Pharm Bull 30: 1369-1373.
19. LIANG YJ, JIAN JH, LIU YC, JUANG SJ, SHYU KG, LAI LP, WANG BW and LEU JG 2010 Advanced glycation end products-induced apoptosis attenuated by PPARdelta activation and epigallocatechin gallate through NF-kappaB pathway in human embryonic kidney cells and human mesangial cells. Diabetes Metab Res Rev 26: 406-416.
20. MAUER SM, STEFFES MW, ELLIS EN, SUTHERLAND DE, BROWN DM and GOETZ FC 1984 Structural-functional relationships in diabetic nephropathy. J Clin Invest 74: 1143-1155.
21. MERELES D and HUNSTEIN W 2011 Epigallocatechin-3-gallate (EGCG) for Clinical Trials: More Pitfalls than Promises? Int J Mol Sci 12: 5592-5603.
22. MIAO L and STCLAIR DK 2009 Regulation of superoxide dismutase genes: implications in disease. Free Radic Biol Med 47: 344-356.
23. PACKER L, TRITSCHLER HJ and WESSEL K 1997 Neuro-protection by the metabolic antioxidant alpha-lipoic acid. Free Radic Biol Med 22: 359-378.
24. PENG A, YE T RAKHEJA D, TU Y, WANG T, DU Y, ZHOU JK, VAZIRI ND, HU Z, MOHAN C and ZHOU XJ 2011 The green tea polyphenol (-)-epigallocatechin-3-gallate ameliorates experimental immune-mediated glomerulonephritis. Kidney Int 80: 601-611.
25. SINGH BN, SHANKAR S and SRIVASTAVA RK 2011 Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochem Pharmacol 82: 1807-1821.
26. SINGH R, AKHTAR N and HAQQI TM 2010 Green tea polyphenol epigallocatechin-3-gallate: inflammation and arthritis. [corrected]. Life Sci 86: 907-918.
27. SINGH U and JIALAL I 2008 Alpha-lipoic acid supplementation and diabetes. Nutr Rev 66: 646-657.
28. SOURRIS KC, HARCOURT BE, PENFOLD SA, YAP FY, MORLEY AL, MORGAN PE, DAVIES MJ, BAKER ST, JERUMS G and FORBES JM 2010 Modulation of the cellular expression of circulating advanced glycation end-product receptors in type 2 diabetic nephropathy. Exp Diabetes Res 2010: 974681.
29. WATANABE K et al. 2010 Role of differential signaling pathways and oxidative stress in diabetic cardiomyopathy. Curr Cardiol Rev 6: 280-290.
30. WOLFRAM S 2007 Effects of green tea and EGCG on cardiovascular and metabolic health. J Am Coll Nutr 26: 373S-388S.
31. YAMABE N, YOKOZAWA T, OYA T and KIM M 2006 Therapeutic potential of (-)-epigallocatechin 3-O-gallate on renal damage in diabetic nephropathy model rats. J Pharmacol Exp Ther 319: 228-236.
32. YAMAGISHI S 2011 Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes. Exp Gerontol 46: 217-224.
33. YAMAGISHI S and IMAIZUMI T 2005 Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 11: 2279-2299.
34. YAMAGISHI S and MATSUI T 2010 Advanced glycation end products, oxidative stress and diabetic nephropathy. Oxid Med Cell Longev 3: 101-108.
35. YAN SD, SCHMIDT AM, Anderson GM, ZHANG J, BRETT J, ZOU YS, PINSKY D and STERN D 1994 Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 269: 9889-9897.
36. YAN SF, RAMASAMY R and SCHMIDT AM 2010 The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature. Circ Res 106: 842-853.
37. YANG H, JIN X, KEI LAM CW and YAN SK 2011 Oxidative stress and diabetes mellitus. Clin Chem Lab Med 49: 1773-1782.
38. YAO D and BROWNLEE M 2010 Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE lig and s. Diabetes 59: 249-255.
39. YILMAZ O, OZKAN Y, YILDIRIM M, OZTURK AI and ERSAN Y 2002 Effects of alpha lipoic acid, ascorbic acid-6-palmitate, and fish oil on the glutathione, malonaldehyde, and fatty acids levels in erythrocytes of streptozotocin induced diabetic male rats. J Cell Biochem 86: 530-539.
40. ZIEGLER D et al. 2006 Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care 29: 2365-2370.